Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Mursla Bio receives FDA breakthrough device designation for EvoLiver test

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy technology, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its lead product, EvoLiver™.

23 Apr 2025

Multi-omics analysis uncovers molecular drivers of non-viral liver cancer development

Researchers discover that inflammation and aging contribute to non-viral liver cancer development. Green tea's role in reversing some of the pathway dysregulation that may contribute to the cancer development and other therapies explored.

15 Apr 2025

Besifovir dipivoxil maleate offers comparable efficacy and improved safety for hepatitis B patients

Hepatitis B is a liver infection cause by the hepatitis B virus (HBV), and long-term hepatitis B infections that last longer than six months are considered "chronic".

24 Mar 2025

Cancer recurrence linked to residual disease missed by imaging

A new editorial was published in Oncotarget, Volume 16, on March 13, 2025, titled "No disease left behind."

22 Mar 2025

Review explores the underlying mechanisms of hepatocarcinogenesis post-HCV eradication

Hepatitis C virus (HCV) infection remains a major global health burden, affecting millions worldwide and contributing significantly to hepatocellular carcinoma (HCC) development.

20 Mar 2025

Researchers move closer to a functional cure for chronic hepatitis B

Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

17 Mar 2025

Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.

14 Mar 2025

Impact of excessive alcohol consumption on digestive health

Excessive alcohol consumption is a significant public health concern, responsible for approximately 6% of all deaths and contributing to 5.1% of the global disease burden.

12 Mar 2025

Nwd1 gene linked to liver dysfunction in metabolic disease

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated with significant global public health concerns.

11 Mar 2025

Breakthrough study defines ideal interval for immunotherapy and liver transplants

Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new cases and 830,200 deaths were registered in 2020 according to the World Health Organization.

6 Mar 2025

New drug candidate may help combat metabolic dysfunction-associated steatotic liver disease

A study published in Nature Aging has revealed a promising new drug candidate that may help combat metabolic dysfunction-associated steatotic liver disease (MASLD), a chronic liver condition that disproportionately affects communities in San Antonio due to high rates of obesity and diabetes.

5 Mar 2025

Novel mechanism of PDHX acetylation linked to hepatocellular carcinoma progression

Cancer cells are known to favor aerobic glycolysis for energy production, a phenomenon termed the Warburg effect.

3 Mar 2025

Review sheds light on the mechanistic role of long non-coding RNAs in liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a global health challenge, affecting nearly 30% of adults worldwide.

28 Feb 2025

CPRIT awards nearly $23 million to MD Anderson for cancer research projects

The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical and prevention science.

20 Feb 2025

Novel therapeutic approaches targeting the Wnt pathway in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.

19 Feb 2025

Icaritin softgel capsules offer new hope for hepatocellular carcinoma patients

Announcing a new publication for Acta Materia Medica journal. Icaritin (ICA) is a prenylflavonoid natural product extracted from plants of the Epimedium genus.

17 Feb 2025

Insilico Medicine develops highly selective FGFR2/3 dual inhibitor for cancer treatment

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma.

7 Feb 2025

Study links low levels of PM2.5 exposure to liver damage

Researchers examine the liver toxicity of low levels of PM2.5 exposure.

5 Feb 2025

New delivery system could improve the effectiveness of peptide-based cancer vaccines

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, according to a new study published in Advanced Functional Materials.

28 Jan 2025

AGA releases updated guidelines on hepatitis B reactivation in patients on immunosuppressive drugs

The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive drugs.

23 Jan 2025